NorthWest Biotherapeutics Inc (NWBO)

[Rkmatters]

Also very exciting in September we released information about 55 patients who had not been enrolled in the Phase III trial because they were too sick to meet the eligibility criteria. After they had surgery to remove the tumor tissue and six weeks of daily radiation and chemotherapy, already by then the tumor was re-growing or appearing to. That kind of a patient is, has such an aggressive form of cancer that normally they don't respond anything. But we had already made the product for those patients because we make it while they're going through the six weeks of radiation. So as a compassionate use, we allowed those patients to be treated with the same DCVax product as in the clinical trial, on the same treatment schedule, at the same clinical trial sites, in the same time period, with the data collected by the same CRO, as the trial and maintained. And that data when we released it, showed that these patients who normally wouldn't be expected to only have survival in the 7 to 10 month range had survival in the 18 -19 months range. So the patients who are even to sick to be in the trial really were getting a major benefit from the treatment. That was a very encouraging set of additional data this year.--LP at Oppenheimer

Not a lie. "Appearing to" makes it very clear. And, by the way 15.3 months mOS still makes her statement true.